SEC Form 4 · accession 0000899243-17-012930
Eledon Pharmaceuticals, Inc. · ELDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christine Ocampo
Officer — See Remarks
Period of report
May 10, 2017
Accepted (ET)
May 11, 2017 · 8:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001404281
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 10, 2017 | P | 10,010 | $9.99 | A | 21,590 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1All numbers give effect to the 1:9 reverse stock split effected by the Company on May 11, 2017.
Remarks
Chief Financial and Compliance Officer